Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy

Prostate cancer patients routinely undergo surveillance for recurrence using prostate-specific antigen (PSA). While PSA’s benefit in screening is controversial, its use for detecting recurrence in patients with history of prostate cancer is pivotal. Rising PSAs with the newly advanced prostate-speci...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in urology 2023-02, Vol.2023, p.7301284-3
Main Authors: Williams, Andrew, Elbakry, Amr A., Trump, Tyler, Prisneac, Ion, Smolkin, Matthew, Zekan, David, Salkini, Mohamad W.
Format: Article
Language:English
Subjects:
Abdomen
Antigens
Cancer patients
Cancer therapies
Care and treatment
Case Report
Case reports
Diseases
Laparoscopy
Lymphatic system
Medical screening
Metastasis
Patients
PET imaging
Prostate cancer
Radiation therapy
Relapse
Surveillance
Tomography
Urology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate cancer patients routinely undergo surveillance for recurrence using prostate-specific antigen (PSA). While PSA’s benefit in screening is controversial, its use for detecting recurrence in patients with history of prostate cancer is pivotal. Rising PSAs with the newly advanced prostate-specific membrane antigen positron emission tomography (PSMA PET) can help localize the location of recurrences for better excision and management. Here, we present a 55-year-old with prostate cancer, with initially undetectable postprostatectomy PSA levels, who later presented with a PSA of 3.47 ng/mL. PSMA PET showed isolated uptake in an abdominal wall mass. Pelvic lymphadenectomy and abdominal wall mass excision were performed, confirming a single metastasis in an abdominal wall lymph node. Metastasectomy led to a dramatic drop in PSA to 0.10 ng/mL both postoperatively and on long-term follow-up. Our case illustrates the potential benefit of metastasis-directed therapy in delayed oligometastasis following definitive management of prostate cancer.
ISSN:2090-696X
2090-6978
DOI:10.1155/2023/7301284